

Table 7.6a
Immunosuppression Use for Induction, 1999 to 2008
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008
Transplants	220	305	305	375	344	420	343	293	261	214
With Immunosuppression Info	217	299	303	372	336	409	337	283	249	206
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	8.3%	1.7%	0.3%	2.4%	0.6%	1.5%	3.3%	0.0%	1.2%	1.0%
OKT3	8.8%	3.0%	0.7%	1.3%	0.9%	0.2%	0.0%	0.7%	0.4%	1.0%
Thymoglobulin	30.0%	37.1%	50.5%	51.9%	50.9%	57.2%	53.7%	56.2%	61.4%	51.9%
Zenapax	36.9%	32.4%	33.3%	25.3%	9.5%	6.6%	6.8%	2.5%	2.0%	4.4%
Simulect	10.6%	17.1%	13.2%	8.3%	8.0%	5.4%	2.7%	6.7%	4.0%	8.3%
Campath	0.0%	0.0%	0.0%	0.0%	13.4%	19.1%	18.4%	13.4%	12.0%	15.0%
No Induction Drugs Recorded	33.6%	33.4%	25.1%	27.2%	25.9%	20.3%	22.0%	21.9%	20.5%	20.4%

Source: OPTN/SRTR Data as of May 4, 2009.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.